Core Structure–Activity Relationship Studies of 5,7,20-O-Trimethylsilybins in Prostate Cancer Cell Models
Open Access
- 2 April 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (4) , 531
Abstract
Silibinin, also known as silybin, is isolated from milk thistle (Silybum marianum). Silibinin has been demonstrated to be a good lead compound due to its potential to prevent and treat prostate cancer. Its moderate potency and poor pharmacokinetic profile hindered it from moving forward to therapeutic use. Our research group has been working on optimizing silibinin for the potential treatment of castration-resistant prostate cancer. Our previous studies established 5,7,20-O-trimethylsilybins as promising lead compounds as they can selectively suppress androgen receptor (AR)-positive LNCaP cell proliferation. Encouraged by the promising data, the present study aims to investigate the relationships between the core structure of 5,7,20-O-trimethylsilybin and their antiproliferative activities towards AR-positive (LNCaP) and AR-negative prostate cancer cell lines (PC-3 and DU145). The structure–activity relationships among the four different core structures (including flavanonol-type flavonolignan (silibinin), flavone-type flavonolignan (hydnocarpin D), chalcone-type flavonolignan, and taxifolin (a flavonolignan precursor) indicate that 5,7,20-O-trimethylsilybins are the most promising scaffold to selectively suppress AR-positive LNCaP prostate cancer cell proliferation. Further investigation on the antiproliferative potency of their optically enriched versions of the most promising 5,7,20-O-trimethylsilybins led to the conclusion that (10R,11R) derivatives (silybin A series) are more potent than (10S,11S) derivatives (silybin B series) in suppressing AR positive LNCaP cell proliferation.Keywords
Funding Information
- Scholarly and Creative Activity Award from the College of Science and Mathematics at California State University Fresno (2G12MD007595-064, 1U54GM104940)
- NIH RCMI program at Xavier University of Louisiana (2G12MD007595-064, 1U54GM104940)
- NIGMS-NIH (2G12MD007595-064, 1U54GM104940)
This publication has 37 references indexed in Scilit:
- Flavokawain B, a kava chalcone, induces apoptosis via up‐regulation of death‐receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growthInternational Journal of Cancer, 2010
- Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF‐κB, and androgen receptor signalingMolecular Carcinogenesis, 2010
- Chalcones and Dihydrochalcones Augment TRAIL-Mediated Apoptosis in Prostate Cancer CellsMolecules, 2010
- Isoliquiritigenin, a natural anti‐oxidant, selectively inhibits the proliferation of prostate cancer cellsClinical and Experimental Pharmacology and Physiology, 2010
- Syntheses and potential anti-prostate cancer activities of ionone-based chalconesBioorganic & Medicinal Chemistry Letters, 2009
- Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathwayOncogene, 2008
- Dietary Feeding of Silibinin Inhibits Prostate Tumor Growth and Progression in Transgenic Adenocarcinoma of the Mouse Prostate ModelCancer Research, 2007
- Milk Thistle and Prostate Cancer: Differential Effects of Pure Flavonolignans from Silybum marianum on Antiproliferative End Points in Human Prostate Carcinoma CellsCancer Research, 2005
- Silibinin Down-Regulates Prostate Epithelium-Derived Ets Transcription Factor in LNCaP Prostate Cancer CellsPlanta Medica, 2004
- Inhibition of Telomerase Activity and Secretion of Prostate Specific Antigen by Silibinin in Prostate Cancer CellsJournal of Urology, 2004